Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Metformin

Endocrinology_Today

Endocrinology Today—July 7, 2026

This week’s Endocrinology update highlights regulatory approvals, chronic…

Respiratory

Respiratory Today—January 23, 2026

This update highlights significant advancements in clinical trials, regulatory…

Endocrinology

Endocrinology Today—November 18, 2025

Weekly Endocrinology update spotilighting regulatory developments, clinical…

Endocrinology

Endocrinology Weekly Update - August 26th 2025

🧬 Endocrinology Update: AI Predicts Insulin Resistance, Ozempic Kidney…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
LucidScope AI Audit Analyses
Public Health News
Monthly Strategic Roundups
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Conavi Medical Raises C$10 Million in Public Offering | Lucid Diligence Brief
Insulinova Partners with Ospedale San Raffaele | Lucid Diligence Brief
Rare Diseases Strategic Roundup | July 08 – Aug 12, 2026
Oncology Strategic Roundup | July 02 – Aug 07, 2026
Vaccine Strategic Roundup I July 06 – Aug 07, 2026

Tags

AAV Gene Therapy ACC 2025 ACLF ailux Attention Deficit Hyperactivity Disorder Azafaros Beclometasone/Formoterol Blinatumomab cholera commercial launches Corneal Endothelial Disease Coronavirus Disease 2019 Daewon Pharmaceutical Elecsys pTau181 epidermolysis bullosa Fanconi anemia geneventiv therapeutics Global Health Research graft-versus-host disease Healthcare AI Infrastructure IAS 2025 Imviva Biotech Infex Therapeutics Isomorphic Labs Lebrikizumab MajesTEC-9 Major depressive disorder Mirai Bio Motixafortide mursla bio Namodenoson Nanox.AI nvidia Oxaliplatin PCSK9 inhibitor ProFound Therapeutics progressive multiple sclerosis RA Capital RATIONALE-309 RNAi therapeutics roflumilast 0.05% strategic collaboration Surgical retina TCT Vanzacaftor/Tezacaftor/Deutivacaftor

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Conavi Medical Raises C$10 Million in Public Offering | Lucid Diligence Brief
Insulinova Partners with Ospedale San Raffaele | Lucid Diligence Brief
Rare Diseases Strategic Roundup | July 08 – Aug 12, 2026
Oncology Strategic Roundup | July 02 – Aug 07, 2026
Vaccine Strategic Roundup I July 06 – Aug 07, 2026

TAGS

AAV Gene Therapy ACC 2025 ACLF ailux Attention Deficit Hyperactivity Disorder Azafaros Beclometasone/Formoterol Blinatumomab cholera commercial launches Corneal Endothelial Disease Coronavirus Disease 2019 Daewon Pharmaceutical Elecsys pTau181 epidermolysis bullosa Fanconi anemia geneventiv therapeutics Global Health Research graft-versus-host disease Healthcare AI Infrastructure IAS 2025 Imviva Biotech Infex Therapeutics Isomorphic Labs Lebrikizumab MajesTEC-9 Major depressive disorder Mirai Bio Motixafortide mursla bio Namodenoson Nanox.AI nvidia Oxaliplatin PCSK9 inhibitor ProFound Therapeutics progressive multiple sclerosis RA Capital RATIONALE-309 RNAi therapeutics roflumilast 0.05% strategic collaboration Surgical retina TCT Vanzacaftor/Tezacaftor/Deutivacaftor

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy